Fujita, Akiko <br/><br/>
A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.  [electronic resource] 

 -  Experimental animals  2012 
 - 49-57 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1881-7122 
<br/><br/><label>Standard No.: </label>10.1538/expanim.61.49  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>8-Hydroxy-2'-Deoxyguanosine<br/>Angiotensin II Type 1 Receptor Blockers--therapeutic use<br/>Animals<br/>Benzimidazoles--therapeutic use<br/>Biphenyl Compounds--therapeutic use<br/>Deoxyguanosine--analogs & derivatives<br/>Diabetes Mellitus, Experimental--genetics<br/>Diabetes Mellitus, Type 2--physiopathology<br/>Diabetic Nephropathies--drug therapy<br/>Disease Models, Animal<br/>Enzyme-Linked Immunosorbent Assay<br/>Humans<br/>Kidney--pathology<br/>Maf Transcription Factors, Large--genetics<br/>MafK Transcription Factor--genetics<br/>Male<br/>Mice<br/>Mice, Transgenic<br/>Nephrectomy<br/>Tetrazoles--therapeutic use